Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.47 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267681 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL16841696 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL8979913 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL7857698 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL19879529 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL19224560 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL5820623 | 0.86 | CA1 (0.43) | CA1CA2CA9CA12GBA1 | |
| SCHEMBL5820619 | 0.86 | CA1 (0.43) | CA1CA2CA9CA12GBA1 | |
| SCHEMBL23235646 | 0.86 | GRM2 (0.44) | CA1CA2CA9CA12GRM2 | |
| SCHEMBL13971270 | 0.85 | ALDH1A1 (0.46) | CA1CA2CA9CA12GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | CA1 1603/4885CA2 1661/4885CA9 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.